Treatment of Progressive Nodular Histiocytosis With Baricitinib

Abstract

Author Contributions: Mr Cwalina had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Janus kinase inhibitor for multicentric reticulohistiocytosis, a new potential treatment

“…As TNF is of great importance in MRH pathology, as demonstrated by the success of anti‐TNF therapies in MRH treatment, JAKi should be considered a promising treatment option by indirectly suppressing TNF function. Furthermore, JAKi has shown great potential in other histopathologically similar diseases, such as sarcoidosis and progressive nodular histiocytosis 25,26 . Moreover, while pan‐JAKi will provide maximal efficacy, they carry the greatest risk of toxicity due to broad pathway suppression.…”